Related Experiment Video
Updated: Jul 14, 2026

Non-Invasive Endotracheal Administration of Lipopolysaccharide to Induce Acute Lung Injury in Rodents
Published on: December 5, 2025
Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections
Madison E Salam1,2, Daniel B Chastain3, Douglas Fish1
1Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, 80045, USA.
Abstract:
Gram-positive infections continue to pose a therapeutic challenge owing to their invasive nature (e.g., Staphylococcus aureus and Streptococcus pyogenes) and eradication difficulties (e.g., methicillin-resistant Staphylococcus aureus [MRSA] and vancomycin-resistant enterococci [VRE]). Long-acting lipoglycopeptides (laLGPs) present an effective and conveniently dosed option for the treatment of most invasive Gram-positive pathogens. Improved compliance monitoring associated with their infrequent intravenous dosing, that is not available to such degree with more frequently dosed antimicrobials outside of inpatient settings, is another benefit of laLGPs over more frequently dosed antimicrobials. In this article, we provide a narrative review, including the pharmacological characteristics of dalbavancin (DAL) and oritavancin (ORI), the only currently available laLGPs, as well as their approved and "off-label" use reported in the literature to date. We discuss their respective mechanism of action, caveats in compartments where they do not achieve sufficient concentrations (i.e., central nervous system [CNS]; potentially pneumonias with ORI), as well as their reported efficacy in individual organ systems as reported in literature. Lastly, we summarize insights about laLGP use in special populations and discuss the benefits of therapeutic drug monitoring of these agents, mainly in conditions requiring prolonged therapy (e.g., hardware-associated orthopedic infections).
Insights
Long-acting lipoglycopeptides (laLGPs) offer effective treatment for invasive Gram-positive infections like MRSA and VRE. Their infrequent dosing improves patient compliance compared to frequently administered antimicrobials.
Area of Science:
- Pharmacology
- Infectious Diseases
- Antimicrobial Therapy
Background:
- Gram-positive infections caused by pathogens like Staphylococcus aureus and Streptococcus pyogenes present significant therapeutic challenges.
- Emergence of resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) complicates treatment.
- Long-acting lipoglycopeptides (laLGPs) have emerged as a valuable therapeutic option for these difficult-to-treat infections.
Purpose of the Study:
- To provide a narrative review of currently available long-acting lipoglycopeptides (laLGPs).
- To discuss the pharmacological characteristics, mechanism of action, and clinical applications of dalbavancin (DAL) and oritavancin (ORI).
- To explore their efficacy, limitations, and use in special populations, including the role of therapeutic drug monitoring.
Main Methods:
- Narrative review of existing literature on dalbavancin and oritavancin.
- Analysis of pharmacological properties, including mechanism of action and tissue distribution.
- Synthesis of reported clinical data on approved and off-label uses, efficacy, and safety.
Main Results:
- Dalbavancin and oritavancin are the only laLGPs currently available, offering convenient dosing for Gram-positive infections.
- These agents demonstrate efficacy across various applications but have limitations in achieving sufficient concentrations in certain body compartments like the central nervous system.
- Literature reports efficacy in specific organ systems and highlights benefits in special populations, particularly for hardware-associated infections.
Conclusions:
- Long-acting lipoglycopeptides provide an effective and compliant treatment strategy for invasive Gram-positive infections.
- Understanding their pharmacokinetic profiles and limitations is crucial for optimal clinical application.
- Therapeutic drug monitoring may be beneficial in specific scenarios, such as prolonged therapy for orthopedic hardware infections.
More Related Videos
10:59Enrichment of Bacterial Lipoproteins and Preparation of N-terminal Lipopeptides for Structural Determination by Mass Spectrometry
Published on: May 21, 2018
11:59Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids
Published on: May 15, 2019
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Formation of Lipopolysaccharides
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Production of Pharmaceuticals